Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, Dongol, Sabina, Karkey, Abhilasha, Thompson, Corinne N, Thieu, Nga Tran Vu, Thanh, Duy Pham, Baker, Stephen, Thwaites, Guy E, Wolbers, Marcel, Dolecek, Christiane
Format: Technical Report
Jezik:en_US
Izdano: Lancet Infect Dis 2016 2016
Teme:
Gatifloxacin versus
Enteric Fever
Nepal
Online pristup:http://103.69.126.140:8080/handle/123456789/818
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
Opis
Sažetak:Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.

Similar Items